{
    "clinical_study": {
        "@rank": "154788", 
        "arm_group": [
            {
                "arm_group_label": "PF-05212377 70 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "PF-05212377 20 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "PF-05212377 10 mg", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will see how PF-05212377, an experimental drug to treat symptoms from Alzheimer's\n      Disease, distributes in the brain after one dose of PF-05212377 is administered orally to\n      healthy volunteer subjects. The study will also evaluate the safety and tolerability of\n      PF-05212377 in these subjects and will measure the level of PF-05212377 in the blood."
        }, 
        "brief_title": "A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females must be at least 18 years of age and no older than 55 years of age\n             with a Body Mass Index (BMI) must be between 17.5 and 30.5.\n\n          -  Subjects must sign a consent form and comply with all scheduled visits, treatment\n             plan, lab tests and other study procedures.\n\n        Exclusion Criteria:\n\n          -  Females must not be pregnant, breastfeeding, or able to have children.\n\n          -  Subjects must not have a severe acute or chronic medical or psychiatric condition\n             history or evidence of blood, kidney, glandular, lung, stomach, intestine, heart,\n             blood vessel, liver, psychiatric, nerve, or allergic problems (including drug\n             allergies), except mild seasonal allergies.\n\n          -  Subjects must not drink alcohol excessively or take illicit drugs.\n\n          -  Male subjects use condoms to prevent the potential transfer of drug through the semen\n             to their partner beginning with the dose of study drug and use a highly effective\n             method of birth control with any partner(s) of childbearing potential through 28 days\n             after the last dose."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "4", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005991", 
            "org_study_id": "B2081015"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-05212377 70 mg", 
                "description": "Single, oral dose administration of 70 mg PF-0521377 using a capsule formulation.", 
                "intervention_name": "PF-05212377", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PF-05212377 20 mg", 
                "description": "Single, oral dose administration of 20 mg PF-0521377 using a capsule formulation.  This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arm 1.", 
                "intervention_name": "PF-05212377", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PF-05212377 10 mg", 
                "description": "Single, oral dose administration of 10 mg PF-0521377 using a capsule formulation.  This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arms 1 and 2.", 
                "intervention_name": "PF-05212377", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "PF-05212377", 
            "phase 1", 
            "open-label", 
            "5-HT2a receptor occupancy", 
            "positron emission tomography", 
            "healthy subjects", 
            "brain", 
            "cortex", 
            "alzheimers disease"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2081015&StudyName=A%20Study%20To%20Examine%20The%20Distribution%20Of%20PF-05212377%20In%20The%20Brain%20Of%20Healthy%20Volunteer%20Subjects%20Using%20Positron%20Emission%20Tomography%20And%20A"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06519"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06511"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06520"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Open-Label Study To Evaluate 5-HT2a Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11C]MDL100907 Following Single Oral Dose Administration Of PP-05212377 (SAM-760) In Healthy Subjects", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "5-HT2a receptor occupancy of PF-05212377 in the frontal cortex using PET", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 2"
            }, 
            {
                "measure": "Plasma PF-05212377 exposure associated with PF-05212377 5-HT2a receptor occupancy", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 2"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005991"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "5-HT2a receptor occupancy of PF-05212377 in other cortical regions", 
            "safety_issue": "No", 
            "time_frame": "Day 1 and 2"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}